Why the study?
Does the assay of circulating heart-reactive antibody predict cardiac rejection in patients with cardiac allografts?
Does the assay of circulating heart-reactive antibody predict cardiac rejection in patients with cardiac allografts?
Assay of heart-reactive antibody may serve as an early and sensitive indicator of cardiac rejection in heart transplant recipients before significant cardiac dysfunction occurs.
Answers are grounded in this paper and cite their sources.
May signal early rejection in heart transplant recipients; hypothesis-generating and requires prospective validation before clinical adoption.
Immunofluorescent heart-reactive antibody was demonstrated in serum samples from three patients with cardiac transplants, one of whom is herewith presented in detail. The presence of this antibody correlated well with subsequent episodes of cardiac rejection. Increasing doses of immunosuppressive therapy had a direct effect on the disappearance of the circulating antibody from the serum samples of these patients. Up to the present, all signs and tests for cardiac rejection have relied upon the detection of the signs and effects of cardiac dysfunction, which of course means that significant damage has already occurred. Assay of heart-reactive antibody may be an early and sensitive indicator of cardiac rejection in patients with cardiac allografts.
No takes yet. Share an insight, caveat, or question.
Robert J. Ellis (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: